Cell Bio Human Tech Co.,Ltd (KOSDAQ:318160)
South Korea · Delayed Price · Currency is KRW 6,980.00
-210.00 (-2.92%)
At close: Sep 16, 2026
KOSDAQ:318160 Revenue
Cell Bio Human Tech Co.,Ltd had revenue of 19.36B KRW in the quarter ending June 30, 2026, with 38.43% growth. This brings the company's revenue in the last twelve months to 60.90B, up 61.93% year-over-year. In the year 2025, Cell Bio Human Tech Co.,Ltd had annual revenue of 51.07B with 79.69% growth.
Revenue (ttm)
60.90B
Revenue Growth
+61.93%
P/S Ratio
0.96
Revenue / Employee
812.01M
Employees
75
Market Cap
58.44B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 51.07B | 22.65B | 79.69% |
| Dec 31, 2024 | 28.42B | 1.09B | 4.01% |
| Dec 31, 2023 | 27.32B | -220.33M | -0.80% |
| Dec 31, 2022 | 27.54B | -7.62B | -21.66% |
| Dec 31, 2021 | 35.16B | 6.57B | 22.99% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| OPTRONTEC | 225.67B |
| Amosense | 116.93B |
| Wiable | 74.73B |
| Psomagen | 60.70B |
| Revu Corporation | 58.79B |
| Obigo | 43.11B |
| G.I. Tech | 38.81B |
| VECT Co.,Ltd. | 38.75B |